Successful living kidney transplantation in a T-cell flow cytometry crossmatch-positive patient with atypical hemolytic uremic syndrome treated with an anti-C5 antibody: a case report - PubMed
7 days ago
- #Kidney Transplantation
- #aHUS
- #Eculizumab
- A 41-year-old female with end-stage kidney disease and atypical hemolytic uremic syndrome (aHUS) underwent successful living kidney transplantation.
- Preoperative evaluation revealed ABO incompatibility and strong T-cell flow cytometry crossmatch (FCXM) positivity due to anti-HLA antibodies from prior blood transfusions.
- Treatment with eculizumab (anti-C5 antibody) and desensitization therapy (IVIG, plasma exchange, rituximab) was initiated before transplantation.
- Post-transplant, the patient maintained stable renal function without antibody-mediated rejection (ABMR) or thrombotic microangiopathy (TMA) recurrence.
- Biopsies at 3 months and 1 year confirmed no ABMR or TMA, demonstrating the efficacy of preemptive eculizumab and desensitization.